UY39062A - Complejo polipeptídico producido en una célula cho que comprende polipéptidos de il-15 y de il-15ralfa - Google Patents

Complejo polipeptídico producido en una célula cho que comprende polipéptidos de il-15 y de il-15ralfa

Info

Publication number
UY39062A
UY39062A UY0001039062A UY39062A UY39062A UY 39062 A UY39062 A UY 39062A UY 0001039062 A UY0001039062 A UY 0001039062A UY 39062 A UY39062 A UY 39062A UY 39062 A UY39062 A UY 39062A
Authority
UY
Uruguay
Prior art keywords
15ralfa
polypeptides
cho cell
cell including
complex produced
Prior art date
Application number
UY0001039062A
Other languages
English (en)
Inventor
Richard Gabriel
Thomas Jostock
Justyna Jozefczuk
Urs Ulrich Lohrig
Suzanna Jane Dale
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY39062A publication Critical patent/UY39062A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al heterodímero de IL–15/IL–15Ra producido en una línea celular CHO, y método de producción del heterodímero y método de tratamiento utilizando el heterodímero.
UY0001039062A 2020-02-05 2021-02-02 Complejo polipeptídico producido en una célula cho que comprende polipéptidos de il-15 y de il-15ralfa UY39062A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062970485P 2020-02-05 2020-02-05

Publications (1)

Publication Number Publication Date
UY39062A true UY39062A (es) 2021-09-30

Family

ID=74554194

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039062A UY39062A (es) 2020-02-05 2021-02-02 Complejo polipeptídico producido en una célula cho que comprende polipéptidos de il-15 y de il-15ralfa

Country Status (21)

Country Link
US (1) US20210244821A1 (es)
EP (1) EP4100425A1 (es)
JP (2) JP2022522566A (es)
KR (1) KR20220137651A (es)
CN (1) CN115023436A (es)
AR (1) AR121261A1 (es)
AU (1) AU2021215893A1 (es)
BR (1) BR112022014493A2 (es)
CA (1) CA3168469A1 (es)
CL (2) CL2022002094A1 (es)
CO (1) CO2022010860A2 (es)
CR (1) CR20220367A (es)
DO (1) DOP2022000156A (es)
EC (1) ECSP22060286A (es)
IL (1) IL295278A (es)
JO (1) JOP20220174A1 (es)
MX (1) MX2022009611A (es)
PE (1) PE20221509A1 (es)
TW (1) TW202142558A (es)
UY (1) UY39062A (es)
WO (1) WO2021156720A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3195627A1 (en) 2020-10-26 2022-05-05 Stefano FERRARA Il-2/il-15r.beta..gamma. agonist for treating squamous cell carcinoma
JP2023550880A (ja) 2020-10-26 2023-12-06 サイチューン ファーマ 非黒色腫皮膚癌を治療するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト
WO2024097918A1 (en) 2022-11-04 2024-05-10 Novartis Ag Nkg2d fusion protein cancer therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
EP1899364B1 (en) 2005-05-17 2020-02-19 University of Connecticut Compositions and methods for immunomodulation in an organism
WO2007070488A2 (en) 2005-12-12 2007-06-21 The Cbr Institute For Biomedical Research, Inc. Integrin alpha l i domain mutants with increased binding affinity
CA2636111C (en) 2006-01-13 2018-04-03 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
CN108948177B (zh) * 2007-05-11 2022-04-22 阿尔托生物科学有限公司 融合分子与il-15变异体
EP2326531B2 (en) 2008-08-22 2021-01-13 Magna Seating Inc. Disc recliner with reduced backlash
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
DK3327040T3 (da) * 2010-09-21 2021-09-20 Altor Bioscience Corp Multimeriske opløselige il-15-fusionsmolekyler og fremgangsmåder til at fremstille og anvende samme
EP2911684B1 (en) * 2012-10-24 2019-06-19 Novartis Ag Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
ES2731246T3 (es) 2014-04-29 2019-11-14 Novartis Ag Células de vertebrado novedosas y métodos para expresar de forma recombinante un polipéptido de interés
AU2015366795B2 (en) * 2014-12-19 2020-12-17 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex and use thereof
JP7200104B2 (ja) * 2016-08-01 2023-01-06 ヴァイロジン バイオテック カナダ リミテッド 免疫系刺激分子を発現する腫瘍溶解性単純ヘルペスウイルスベクター
SG11201903306SA (en) * 2016-10-21 2019-05-30 Altor Bioscience Corp Multimeric il-15-based molecules
RU2019122408A (ru) * 2017-01-20 2021-02-20 Новартис Аг Средство комбинированной терапии для лечения рака
SG11202007240QA (en) * 2018-02-02 2020-08-28 Novartis Ag Combination of sting agonist and il-15/il15-ra for the treatment of cancer
CN111819203A (zh) * 2018-03-01 2020-10-23 葛莱高托普有限公司 包含抗muc1抗体和il-15的融合蛋白构建体

Also Published As

Publication number Publication date
JOP20220174A1 (ar) 2023-01-30
WO2021156720A1 (en) 2021-08-12
TW202142558A (zh) 2021-11-16
JP2023145622A (ja) 2023-10-11
PE20221509A1 (es) 2022-10-04
CL2022002094A1 (es) 2023-03-10
CO2022010860A2 (es) 2022-08-19
IL295278A (en) 2022-10-01
EP4100425A1 (en) 2022-12-14
ECSP22060286A (es) 2022-09-30
JP2022522566A (ja) 2022-04-20
MX2022009611A (es) 2022-11-07
DOP2022000156A (es) 2022-10-16
KR20220137651A (ko) 2022-10-12
AU2021215893A1 (en) 2022-08-25
US20210244821A1 (en) 2021-08-12
CR20220367A (es) 2022-08-30
AR121261A1 (es) 2022-05-04
CA3168469A1 (en) 2021-08-12
CN115023436A (zh) 2022-09-06
CL2023002447A1 (es) 2024-03-15
BR112022014493A2 (pt) 2022-09-20

Similar Documents

Publication Publication Date Title
UY39062A (es) Complejo polipeptídico producido en una célula cho que comprende polipéptidos de il-15 y de il-15ralfa
CO2020013246A2 (es) Proteínas de fusión interleucina-2/receptor alfa de interleucina-2 y métodos de uso
TWD223223S (zh) 鞋
PE20170908A1 (es) VARIANTES DE INTERFERON a2b
CR11194A (es) Polipeptidos, dominios variables de anticuerpos y antagonistas
AR096058A1 (es) Tratamiento de una formación subterránea con una composición que incluye un microorganismo o un compuesto generado por dicho microorganismo
HN2000000264A (es) Compuesto de 2,4-diamino-pirimidina utiles como supresores de inmunidad
TWD222923S (zh) 鞋
AR094781A1 (es) Anticuerpos anti-her2 (receptor 2 del factor de crecimiento epidérmico humano) altamente galactosilados y sus usos
IT1270220B (it) Disposizione a semiconduttori e procedimento di fabbricazione
TWD223791S (zh) 鞋
TWD223071S (zh) 鞋
TWD223070S (zh) 鞋
SA519401434B1 (ar) سقف خرساني أدوات لإنتاج سقف خرساني وطريقة لإنتاج سقف خرساني
CN204943113U (zh) 一种新型平板照明灯具
TWD219144S (zh) 鞋
CR20230282A (es) Derivados de indol útiles en el tratamiento de afecciones asociadas con cgas
AR121881A1 (es) Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos
TWD222918S (zh) 鞋
TWD222159S (zh) 鞋
Nalin Evaluation and recommendation on Inner Mongolian FDI to Mongolia in the framework of “One Belt, One Road”
PL431696A1 (pl) Ozdoby na znicze
Giunashvili Studia Litteraria Universitatis Iagellonicae Cracoviensis, Volume 14 (2019), Special Issue. A Volume in Honour of Professor Anna Krasnowolska. Editor-in-Chief: Celina Juda
CN204938739U (zh) 地铁管片用人字吊具的活动臂
CL2023003551A1 (es) Fibras de cítricos gelificantes y métodos de fabricación